SCHEMBL6086508

SCHEMBL6086508

O=C(COc1cccc(Cl)c1Cl)Nc1cccc(-c2n[nH]cc2-c2nc3cc4ccccc4cc3o2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
THRB P10828 1/20 0.57
MAPT P10636 6/20 0.53
TP53 P04637 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
USP2 O75604 2/20 0.51
TSHR P16473 2/20 0.51
HSD17B10 Q99714 2/20 0.51
CETP P11597 4/20 0.51
LMNA P02545 2/20 0.50
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
CEPT1 Q9Y6K0 1/20 0.46
FAAH O00519 1/20 0.45
P2RY14 Q15391 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084603 0.83 CETP (0.64) POLBTHRBMAPTTP53RXFP1
SCHEMBL6084732 0.82 P2RY14 (0.54) MAPTTP53CETPKDM4ENPC1
SCHEMBL6083942 0.82 P2RY14 (0.54) POLBMAPTTP53USP2HSD17B10
SCHEMBL6084095 0.81 HSD17B10 (0.48) POLBMAPTTP53USP2TSHR
SCHEMBL6222058 0.81 HSD17B10 (0.47) POLBMAPTTP53USP2TSHR
SCHEMBL6085923 0.81 TP53 (0.47) POLBMAPTTP53USP2TSHR
SCHEMBL6086347 0.80 P2RY14 (0.51) POLBTHRBMAPTUSP2TSHR
SCHEMBL6085707 0.80 TP53 (0.47) POLBTHRBMAPTTP53RXFP1
SCHEMBL6086054 0.79 P2RY14 (0.63) MAPTTP53RXFP1P2RY14
SCHEMBL6084339 0.79 P2RY14 (0.51) POLBMAPTTP53USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 POLB 1679/4885THRB 1963/4885MAPT 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.